Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.001
-
Shares outstanding
-
43.5M
-
Number of holders
-
93
-
Total 13F shares, excl. options
-
43M
-
Shares change
-
+4.15M
-
Total reported value, excl. options
-
$1.11B
-
Value change
-
+$108M
-
Number of buys
-
61
-
Number of sells
-
-17
-
Price
-
$25.93
Significant Holders of Maze Therapeutics, Inc. - Common Stock, par value $0.001 (MAZE) as of Q3 2025
96 filings reported holding MAZE - Maze Therapeutics, Inc. - Common Stock, par value $0.001 as of Q3 2025.
Maze Therapeutics, Inc. - Common Stock, par value $0.001 (MAZE) has 93 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 43M shares
of 43.5M outstanding shares and own 98.79% of the company stock.
Largest 10 shareholders include TRV GP IV, LLC (6.07M shares), Frazier Life Sciences Management, L.P. (4.57M shares), ARCH Venture Management, LLC (4.12M shares), Deep Track Capital, LP (3.95M shares), Alphabet Inc. (2.41M shares), a16z Capital Management, L.L.C. (1.7M shares), Matrix Capital Management Company, LP (1.65M shares), VANGUARD GROUP INC (1.33M shares), BlackRock, Inc. (1.32M shares), and VR ADVISER, LLC (1.23M shares).
This table shows the top 93 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.